ArticleeLife2019
Persistent inflammation during anti-tuberculosis treatment with diabetes comorbidity.
Article in eLife, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Immune dysregulation in tuberculosis-diabetes comorbidity: mechanistic and translational insights.Frontiers in immunology · 2026Pooled it
- Meta-Inflammation in Type 2 Diabetes Mellitus: Theoretical, Methodological, and Clinical Aspects.International journal of molecular sciences · 2026Article
- Glycolysis inhibition in tuberculosis-driven metabolic rewiring reduces HIV-1 spread in macrophages.Life science alliance · 2026Article
- Persistent Hyperglycaemia and Transient Dysglycaemia in Tuberculosis: Evaluating the Bidirectional Interaction With Type-2 Diabetes Mellitus and Clinical Outcomes.Tropical medicine & international health : TM & IH · 2026Article
- Lipid metabolism in the resuscitation of dormant mycobacterium tuberculosis: molecular resilience, host hijacking, and clinical opportunities.Frontiers in cellular and infection microbiology · 2026Review
- Scutellarin suppresses Mycobacterium tuberculosis-induced pyroptosis in macrophages by inhibiting the HIF-1α-mediated Warburg effect.Redox report : communications in free radical research · 2025Article
- Inflammation and dyslipidaemia in combined diabetes and tuberculosis; a cohort study.iScience · 2025Article
- Development and Validation of a Predictive Model Using Inflammatory Biomarkers for Active Tuberculosis Risk in Diabetic Patients.Journal of inflammation research · 2025Article
- Pathogenesis of Post-Tuberculosis Lung Disease: Defining Knowledge Gaps and Research Priorities at the Second International Post-Tuberculosis Symposium.American journal of respiratory and critical care medicine · 2024Review
- Advances in an In Vitro Tuberculosis Infection Model Using Human Lung Organoids for Host-Directed Therapies.PLoS pathogens · 2024Article
- Impact of hyperglycemia on tuberculosis treatment outcomes: a cohort study.Scientific reports · 2024Article
- Article
- Intersecting epidemics: deciphering the complexities of tuberculosis-diabetes comorbidity.Frontiers in tuberculosis · 2024Review
- Longitudinal mitochondrial bioenergetic signatures of blood monocytes and lymphocytes improve during treatment of drug-susceptible pulmonary tuberculosis patients Monocyte/lymphocyte bioenergetic signatures post-TB treatment.Frontiers in immunology · 2024Article
- Assessing the effects of diabetes mellitus on the monocyte-to-lymphocyte ratio and the QuantiFERON-TB gold plus assays for tuberculosis treatment monitoring: a prospective cohort study.Frontiers in immunology · 2024Article
- Tuberculosis survivors and the risk of cardiovascular disease: analysis using a nationwide survey in Korea.Frontiers in cardiovascular medicine · 2024Article
- Variations in Quinolinic Acid Levels in Tuberculosis Patients with Diabetes Comorbidity: A Pilot Prospective Cohort Study.Infection and drug resistance · 2024Article
- Effect of prediabetes on tuberculosis treatment outcomes: A study from South India.Diabetes & metabolic syndrome · 2023Observational
- A multi-center, prospective cohort study of whole blood gene expression in the tuberculosis-diabetes interaction.Scientific reports · 2023Article
- COVID-19, the escalation of diabetes mellitus and the repercussions on tuberculosis.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 5 institutions in 3 countries.
Funding
Abstract
Diabetes mellitus (DM) increases risk for pulmonary tuberculosis (TB) and adverse treatment outcomes. Systemic hyper-inflammation is characteristic in people with TB and concurrent DM (TBDM) at baseline, but the impact of TB treatment on this pattern has not been determined. We measured 17 plasma cytokines and growth factors in longitudinal cohorts of Indian and Brazilian pulmonary TB patients with or without DM. Principal component analysis revealed virtually complete separation of TBDM from TB individuals in both cohorts at baseline, with hyper-inflammation in TBDM that continued through treatment completion at six months. By one year after treatment completion, there was substantial convergence of mediator levels between groups within the India cohort. Non-resolving systemic inflammation in TBDM comorbidity could reflect delayed lesion sterilization or non-resolving sterile inflammation. Either mechanism portends unfavorable long-term outcomes including risk for recurrent TB and for damaging immune pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.